Ral GTPase down-regulation stabilizes and reactivates p53 to inhibit malignant transformation

Journal of Biological Chemistry

Volumn 289, Issue 45, 2014, Pages 31296-31309

  Tecleab, Awet ^a,b   Zhang, Xiaolei ^a   Sebti, Said M ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL GROWTH; CHEMICAL ACTIVATION;

ATAXIA-TELANGIECTASIA MUTATED; CELL-CYCLE PROGRESSION; DOWN-REGULATION; HUMAN CANCER CELLS; KINASE ACTIVATION; MALIGNANT TRANSFORMATIONS; MOLECULAR MECHANISM; UP-REGULATION;

PROTEINS;

ATM PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; GUANOSINE TRIPHOSPHATASE; K RAS PROTEIN; PROTEIN AKT1; PROTEIN KINASE B; PROTEIN KINASE B BETA; PROTEIN P53; RAF PROTEIN; RAL PROTEIN; RALA PROTEIN; RALB PROTEIN; UNCLASSIFIED DRUG; CASPASE; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; PROTEIN P21; RALA PROTEIN, HUMAN; RALB PROTEIN, HUMAN; SERINE; SMALL INTERFERING RNA; TP53 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MUTANT; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; S PHASE CELL CYCLE CHECKPOINT; TRANSCRIPTION REGULATION; UPREGULATION; WILD TYPE; CELL CYCLE; CELL TRANSFORMATION; CHEMISTRY; GENE EXPRESSION REGULATION; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CASPASES; CELL CYCLE; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOWN-REGULATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS P21(RAS); RAL GTP-BINDING PROTEINS; RNA, SMALL INTERFERING; SERINE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84909952634     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.565796     Document Type: Article

References (51)

1. Hanahan, D., and Weinberg, R. A. (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674
2. Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., Teague, J. W., Campbell, P. J., Stratton, M. R., and Futreal, P. A. (2011) COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945-D950
3. Downward, J. (2003) Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3, 11-22
4. Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., and Lane, D. P. (2009) Awakening guardian angels: drugging the p53 pathway. Nat. Rev. Cancer 9, 862-873
5. Ferbeyre, G., de Stanchina, E., Lin, A. W., Querido, E., McCurrach, M. E., Hannon, G. J., and Lowe, S. W. (2002) Oncogenic ras and p53 cooperate to induce cellular senescence. Mol. Cell. Biol. 22, 3497-3508
6. Hirao, A., Kong, Y. Y., Matsuoka, S., Wakeham, A., Ruland, J., Yoshida, H., Liu, D., Elledge, S. J., and Mak, T. W. (2000) DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 287, 1824-1827
7. Sakaguchi, K., Herrera, J. E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C. W., and Appella, E. (1998) DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12, 2831-2841
8. Riley, T., Sontag, E., Chen, P., and Levine, A. (2008) Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol. 9, 402-412
9. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. (1991) p53 mutations in human cancers. Science 253, 49-53
10. Wu, X., Bayle, J. H., Olson, D., and Levine, A. J. (1993) The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7, 1126-1132
11. Honda, R., and Yasuda, H. (1999) Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J. 18, 22-27
12. Ries, S. J., Brandts, C. H., Chung, A. S., Biederer, C. H., Hann, B. C., Lipner, E. M., McCormick, F., and Korn, W. M. (2000) Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat. Med. 6, 1128-1133
13. Tao, W., and Levine, A. J. (1999) P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc. Natl. Acad. Sci. U.S.A. 96, 6937-6941
14. Braig, M., Lee, S., Loddenkemper, C., Rudolph, C., Peters, A. H., Schlegelberger, B., Stein, H., Dörken, B., Jenuwein, T., and Schmitt, C. A. (2005) Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436, 660-665
15. Collado, M., and Serrano, M. (2010) Senescence in tumours: evidence from mice and humans. Nat. Rev. Cancer 10, 51-57
16. Lee, S. H., Lee, S. J., Jung, Y. S., Xu, Y., Kang, H. S., Ha, N. C., and Park, B. J. (2009) Blocking of p53-Snail binding, promoted by oncogenic K-Ras, recovers p53 expression and function. Neoplasia 11, 22-31
17. Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., and Lowe, S. W. (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593-602
18. Ha, L., Ichikawa, T., Anver, M., Dickins, R., Lowe, S., Sharpless, N. E., Krimpenfort, P., Depinho, R. A., Bennett, D. C., Sviderskaya, E. V., and Merlino, G. (2007) ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc. Natl. Acad. Sci. U.S.A. 104, 10968-10973
19. Lin, A. W., and Lowe, S. W. (2001) Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation. Proc. Natl. Acad. Sci. U.S.A. 98, 5025-5030
20. Lowe, S. W. (1999) Activation of p53 by oncogenes. Endocr. Relat. Cancer 6, 45-48
21. Guerra, C., Mijimolle, N., Dhawahir, A., Dubus, P., Barradas, M., Serrano, M., Campuzano, V., and Barbacid, M. (2003) Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 4, 111-120
22. Ries, S., Biederer, C., Woods, D., Shifman, O., Shirasawa, S., Sasazuki, T., McMahon, M., Oren, M., and McCormick, F. (2000) Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 103, 321-330
23. Ogawara, Y., Kishishita, S., Obata, T., Isazawa, Y., Suzuki, T., Tanaka, K., Masuyama, N., and Gotoh, Y. (2002) Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J. Biol. Chem. 277, 21843-21850
24. Wolthuis, R. M., Zwartkruis, F., Moen, T. C., and Bos, J. L. (1998) Ras-dependent activation of the small GTPase Ral. Curr. Biol. 8, 471-474
25. Ferro, E., and Trabalzini, L. (2010) RalGDS family members couple Ras to Ral signalling and that's not all. Cell. Signal. 22, 1804-1810
26. de Bruyn, K. M., de Rooij, J., Wolthuis, R. M., Rehmann, H., Wesenbeek, J., Cool, R. H., Wittinghofer, A. H., and Bos, J. L. (2000) RalGEF2, a pleckstrin homology domain containing guanine nucleotide exchange factor for Ral. J. Biol. Chem. 275, 29761-29766
27. Rebhun, J. F., Chen, H., and Quilliam, L. A. (2000) Identification and characterization of a new family of guanine nucleotide exchange factors for the ras-related GTPase Ral. J. Biol. Chem. 275, 13406-13410
28. Hamad, N. M., Elconin, J. H., Karnoub, A. E., Bai, W., Rich, J. N., Abraham, R. T., Der, C. J., and Counter, C. M. (2002) Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev. 16, 2045-2057
29. Lim, K. H., Brady, D. C., Kashatus, D. F., Ancrile, B. B., Der, C. J., Cox, A. D., and Counter, C. M. (2010) Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA. Mol. Cell. Biol. 30, 508-523
30. Lim, K. H., O'Hayer, K., Adam, S. J., Kendall, S. D., Campbell, P. M., Der, C. J., and Counter, C. M. (2006) Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells. Curr. Biol. 16, 2385-2394
31. Martin, T. D., and Der, C. J. (2012) Differential involvement of RalA and RalB in colorectal cancer. Small GTPases 3, 126-130
32. Martin, T. D., Mitin, N., Cox, A. D., Yeh, J. J., and Der, C. J. (2012) Phosphorylation by protein kinase Cα regulates RalB small GTPase protein activation, subcellular localization, and effector utilization. J. Biol. Chem. 287, 14827-14836
33. Shipitsin, M., and Feig, L. A. (2004) RalA but not RalB enhances polarized delivery of membrane proteins to the basolateral surface of epithelial cells. Mol. Cell. Biol. 24, 5746-5756
34. Chien, Y., and White, M. A. (2003) RAL GTPases are linchpin modulators of human tumour-cell proliferation and survival. EMBO Rep. 4, 800-806
35. Oxford, G., Owens, C. R., Titus, B. J., Foreman, T. L., Herlevsen, M. C., Smith, S. C., and Theodorescu, D. (2005) RalA and RalB: antagonistic relatives in cancer cell migration. Cancer Res. 65, 7111-7120
36. Kodama, M., Otsubo, C., Hirota, T., Yokota, J., Enari, M., and Taya, Y. (2010) Requirement of ATM for rapid p53 phosphorylation at Ser46 without Ser/Thr-Gln sequences. Mol. Cell. Biol. 30, 1620-1633
37. Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., van Tuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., White, R., and Vogelstein, B. (1989) Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244, 217-221
38. Hollstein, M. C., Metcalf, R. A., Welsh, J. A., Montesano, R., and Harris, C. C. (1990) Frequent mutation of the p53 gene in human esophageal cancer. Proc. Natl. Acad. Sci. U.S.A. 87, 9958-9961
39. Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hostetter, R., Cleary, K., Bigner, S. H., Davidson, N., Baylin, S., and Devilee, P. (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342, 705-708
40. Takahashi, T., Nau, M. M., Chiba, I., Birrer, M. J., Rosenberg, R. K., Vinocour, M., Levitt, M., Pass, H., Gazdar, A. F., and Minna, J. D. (1989) p53: a frequent target for genetic abnormalities in lung cancer. Science 246, 491-494
41. 2 arrest after DNA damage. Science 282, 1497-1501
42. Raj, D., Liu, T., Samadashwily, G., Li, F., and Grossman, D. (2008) Survivin repression by p53, Rb and E2F2 in normal human melanocytes. Carcinogenesis 29, 194-201
43. Sionov, R. V., and Haupt, Y. (1999) The cellular response to p53: the decision between life and death. Oncogene 18, 6145-6157
44. Vousden, K. H., and Lu, X. (2002) Live or let die: the cell's response to p53. Nat. Rev. Cancer 2, 594-604
45. Ashcroft, M., Kubbutat, M. H., and Vousden, K. H. (1999) Regulation of p53 function and stability by phosphorylation. Mol. Cell. Biol. 19, 1751-1758
46. Shieh, S. Y., Ikeda, M., Taya, Y., and Prives, C. (1997) DNA damageinduced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91, 325-334
47. Bodemann, B. O., and White, M. A. (2008) Ral GTPases and cancer: linchpin support of the tumorigenic platform. Nat. Rev. Cancer 8, 133-140
48. Rangarajan, A., Hong, S. J., Gifford, A., and Weinberg, R. A. (2004) Species- and cell type-specific requirements for cellular transformation. Cancer Cell 6, 171-183
49. 1 cell cycle progression. J. Biol. Chem. 274, 22033-22040
50. Henry, D. O., Moskalenko, S. A., Kaur, K. J., Fu, M., Pestell, R. G., Camonis, J. H., and White, M. A. (2000) Ral GTPases contribute to regulation of cyclin D1 through activation of NF-κB. Mol. Cell. Biol. 20, 8084-8092
51. De Ruiter, N. D., Burgering, B. M., and Bos, J. L. (2001) Regulation of the Forkhead transcription factor AFX by Ral-dependent phosphorylation of threonines 447 and 451. Mol. Cell. Biol. 21, 8225-8235